Primary care leading statistic - 99% of people are unable to process certain medications as intended

PGx for Primary Care

Primary care providers can use PGx to determine the correct medication and dose along a patient's entire continuum of care.

The AccessDx PGx Profile:

  • Supports continuity of care
  • Enhances clinical decision-making
  • Helps reduce trial-and-error prescribing
  • Aids in improving medication adherence

Fill out this form to learn more details about PGx for primary care.

Name
By filling out this form, you agree to receive communications like newsletters, marketing or promotional materials, and other information from AccessDx Laboratory and our parent company, Aranscia®. You may opt-out of receiving communications from us by using the unsubscribe link at the bottom of all emails or contacting us directly.

Limiting PGx testing to a single clinical area might lead to missed actionable drug-gene interactions and potential patient harm2

Testing Options:

PGx Profile – Comprehensive Panel

Includes 37+ high-evidence and emerging-evidence genes, with four add-on genes available (APOE and HLA risk alleles)

PGx Profile – Focused Panel

Includes 20 high-evidence genes with actionable guidance, including HLA risk alleles

Therapeutic Areas Impacted:

Anestheisology
Behavioral Health
Cardiology
Dermatology

Endocrinology
Gastroenterology
Genitourinary
Hematology

Infectious Disease
Neurology
Oncology & Immunology
Opthalmology

Otolaryngology
Pain Medicine
Rheumatology
Transplant

  1. Chanfreau-Coffinier C, et al. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. JAMA Netw Open. 2019;2(6):e195345.
  2. Ashcraft, Kristine, et al. “Validation of Pharmacogenomic Interaction Probability (PIP) Scores in Predicting Drug–Gene, Drug–Drug–Gene, and Drug–Gene–Gene Interaction
    Risks in a Large Patient Population.” Journal of Personalized Medicine, vol. 12, no. 12, 2022, article 1972, https://doi.org/10.3390/jpm12121972.
  3. Bureau USC. 2017 National Population Projections Tables: Main Series. Census.gov. October 8, 2021. Accessed May 6, 2022.
  4. United States Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. U.S. Food and Drug Administration, last updated June 2024,
    https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. Accessed 8 Aug. 2025.